Jump to content

Macular degeneration

Listen to this article
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Headbomb (talk | contribs) at 12:42, 14 October 2018 (fix). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Macular degeneration
Other namesAge-related macular degeneration
Picture of the back of the eye showing intermediate age-related macular degeneration
SpecialtyOphthalmology
SymptomsBlurred or no vision in the center of the visual field[1]
ComplicationsVisual hallucinations[1]
Usual onsetOlder people[1]
TypesEarly, intermediate, late[1]
CausesDamage to the macula of the retina[1]
Risk factorsGenetics, smoking[1]
Diagnostic methodEye examination[1]
PreventionExercising, eating well, not smoking[1]
TreatmentAnti-VEGF medication injected into the eye, laser coagulation, photodynamic therapy[1]
Frequency6.2 million (2015)[2]

Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field.[1] Early on there are often no symptoms.[1] Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes.[1] While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life.[1] Visual hallucinations may also occur and these do not represent a mental illness.[1]

Macular degeneration typically occurs in older people.[1] Genetic factors and smoking also play a role.[1] It is due to damage to the macula of the retina.[1] Diagnosis is by a complete eye exam.[1] The severity is divided into early, intermediate, and late types.[1] The late type is additionally divided into "dry" and "wet" forms with the dry form making up 90% of cases.[1][3]

Prevention includes exercising, eating well, and not smoking.[1] Antioxidant vitamins and minerals do not appear to be useful for prevention.[4] There is no cure or treatment that returns vision already lost.[1] In the wet form, anti-VEGF medication injected into the eye or less commonly laser coagulation or photodynamic therapy may slow worsening.[1] Supplements in those who already have the disease may slow progression.[5][needs update]

In 2015 it affected 6.2 million people globally.[2] In 2013 it was the fourth most common cause of blindness after cataracts, preterm birth, and glaucoma.[6] It most commonly occurs in people over the age of fifty and in the United States is the most common cause of vision loss in this age group.[1][3] About 0.4% of people between 50 and 60 have the disease, while it occurs in 0.7% of people 60 to 70, 2.3% of those 70 to 80, and nearly 12% of people over 80 years old.[3]

Signs and symptoms

Normal vision
The same view with age-related macular degeneration (National Eye Institute)

Signs and symptoms of macular degeneration include:

Visual symptoms
  • Distorted vision in the form of metamorphopsia, in which a grid of straight lines appears wavy and parts of the grid may appear blank: Patients often first notice this when looking at things like miniblinds in their home or telephone poles while driving. There may also be central scotomas, shadows or missing areas of vision
  • Slow recovery of visual function after exposure to bright light (photostress test)
  • Visual acuity drastically decreasing (two levels or more), e.g.: 20/20 to 20/80
  • Blurred vision: Those with nonexudative macular degeneration may be asymptomatic or notice a gradual loss of central vision, whereas those with exudative macular degeneration often notice a rapid onset of vision loss (often caused by leakage and bleeding of abnormal blood vessels).
  • Trouble discerning colors, specifically dark ones from dark ones and light ones from light ones
  • A loss in contrast sensitivity

Macular degeneration by itself will not lead to total blindness. For that matter, only a small number of people with visual impairment are totally blind. In almost all cases, some vision remains, mainly peripheral. Other complicating conditions may lead to such an acute condition (severe stroke or trauma, untreated glaucoma, etc.), but few macular degeneration patients experience total visual loss.[7]

The area of the macula comprises only about 2.1% of the retina, and the remaining 97.9% (the peripheral field) remains unaffected by the disease. Even though the macula provides such a small fraction of the visual field, almost half of the visual cortex is devoted to processing macular information.[8]

The loss of central vision profoundly affects visual functioning. It is quite difficult, for example, to read without central vision. Pictures that attempt to depict the central visual loss of macular degeneration with a black spot do not do justice to the devastating nature of the visual loss. This can be demonstrated by printing letters six inches high on a piece of paper and attempting to identify them while looking straight ahead and holding the paper slightly to the side. Most people find this difficult to do.

Risk factors

  • Aging: Advanced age is the strongest predictor of AMD, particularly over 50.[9]
  • Family history:

Environment and lifestyle

  • Smoking: Smoking tobacco increases the risk of AMD by two to three times that of someone who has never smoked, and may be the most important modifiable factor in its prevention. A review of previous studies found "a strong association between current smoking and AMD. ... Cigarette smoking is likely to have toxic effects on the retina."[10]
  • Hypertension (high blood pressure): In the ALIENOR study 2013, early and late AMD were not significantly associated with systolic or diastolic BP, hypertension, or use of antihypertensive medications, but elevated pulse pressure ((PP) systolic BP minus diastolic BP) was significantly associated with an increased risk of late AMD.[11]
  • Atherosclerosis:
  • High cholesterol: Elevated cholesterol may increase the risk of AMD[12]
  • Obesity: Abdominal obesity is a risk factor, especially among men[13]
  • Fat intake: Consuming high amounts of certain fats including saturated fats, trans fats and omega-6 fatty acids likely contributes to AMD, while monounsaturated fats are potentially protective.[14] In particular, omega-3 fatty acids may decrease the risk of AMD.[15]
  • Exposure to sunlight,[dubious – discuss] especially blue light: Evidence is conflicting as to whether exposure to sunlight contributes to the development of macular degeneration. A recent study on 446 subjects found it does not.[16] Other research, however, has shown high-energy visible light may contribute to AMD.[17][18]

Genetics

Recurrence ratios for siblings of an affected individual are three- to sixfold higher than in the general population.[19] Genetic linkage analysis has identified 5 sets of gene variants at three locations on different chromosomes (1, 6 and 10) as explaining at least 50% of the risk. These genes have roles regulating the immune response, inflammatory processes and homeostasis of the retina. Variants of these genes give rise to different kinds of dysfunction in these processes. Over time, this results in accumulation of intracellular and extracellular metabolic debris. This can cause scarring of the retina or breakdown of its vascularization.

Genetic tests are available for some of these gene variations. However, pathogenesis of macular degeneration is a complex interaction between genetics, environment and lifestyle, and presence of unfavorable genetic factors doesn't necessarily predict progression to disease. The three loci where identified gene variants are found are designated:

  • Complement Factor H (CFH) on chromosome 1 at location 1q31.3[20]
  • HTRA serine peptidase 1/Age Related Maculopathy Susceptibility 2 (HTRA1/ARMS2) on chromosome 10 at location 10q26
  • Complement Factor B/Complement Component 2 (CFB/CC2) on chromosome 6 at 6p21.3

Specific genes

  • Polymorphisms in genes for complement system proteins: The genes for the complement system proteins factor H (CFH), factor B (CFB) and factor 3 (C3) are strongly associated with a person's risk for developing AMD. CFH is involved in inhibiting the inflammatory response. The mutation in CFH (Y402H) results in reduced ability of CFH to regulate complement on critical surfaces such as the retina and leads to increased inflammatory response within the macula. Absence of the complement factor H-related genes R3 and R1 protects against AMD.[21][22] Two independent studies in 2007 showed a certain common mutation Arg80Gly in the C3 gene, which is a central protein of the complement system, is strongly associated with the occurrence of AMD.[23][24] The authors of both papers consider their study to underscore the influence of the complement pathway in the pathogenesis of this disease.
  • In two 2006 studies, another gene that has implications for the disease, called HTRA1 (encoding a secreted serine protease), was identified.[25][26]
  • Six mutations of the gene SERPING1 (Serpin Peptidase Inhibitor, Clade G (C1 Inhibitor), Member 1) are associated with AMD. Mutations in this gene can also cause hereditary angioedema.[27]
  • Fibulin-5 mutation: Rare forms of the disease are caused by genetic defects in fibulin-5, in an autosomal dominant manner. In 2004, Stone et al. performed a screen on 402 AMD patients and revealed a statistically significant correlation between mutations in fibulin-5 and incidence of the disease.

such as that in the MT-ND2 molecule, predicts wet AMD.[28][29]

Pathophysiology

Human eye cross-sectional view

The pathogenesis of age-related macular degeneration is not well known, although some theories have been put forward, including oxidative stress, mitochondrial dysfunction, and inflammatory processes.

The imbalance between the production of damaged cellular components and degradation leads to the accumulation of harmful products, for example, intracellular lipofuscin and extracellular drusen. Incipient atrophy is demarcated by areas of retinal pigment epithelium (RPE) thinning or depigmentation that precede geographic atrophy in the early stages of AMD. In advanced stages of AMD, atrophy of the RPE (geographic atrophy) and/or development of new blood vessels (neovascularization) result in the death of photoreceptors and central vision loss.

In the dry (nonexudative) form, cellular debris called drusen accumulates between the retina and the choroid, causing atrophy and scarring to the retina. In the wet (exudative) form, which is more severe, blood vessels grow up from the choroid (neovascularization) behind the retina which can leak exudate and fluid and also cause hemorrhaging.

Early work demonstrated a family of immune mediators was plentiful in drusen.[30] Complement factor H (CFH) is an important inhibitor of this inflammatory cascade, and a disease-associated polymorphism in the CFH gene strongly associates with AMD.[31][32][33][34][35] Thus an AMD pathophysiological model of chronic low grade complement activation and inflammation in the macula has been advanced.[36][37] Lending credibility to this has been the discovery of disease-associated genetic polymorphisms in other elements of the complement cascade including complement component 3 (C3).[38]

A powerful predictor of AMD is found on chromosome 10q26 at LOC 387715. An insertion/deletion polymorphism at this site reduces expression of the ARMS2 gene though destabilization of its mRNA through deletion of the polyadenylation signal.[39] ARMS2 protein may localize to the mitochondria and participate in energy metabolism, though much remains to be discovered about its function.

Other gene markers of progression risk includes tissue inhibitor of metalloproteinase 3 (TIMP3), suggesting a role for extracellular matrix metabolism in AMD progression.[40] Variations in cholesterol metabolising genes such as the hepatic lipase, cholesterol ester transferase, lipoprotein lipase and the ATP-binding cassette A1 correlate with disease progression. The early stigmata of disease, drusen, are rich in cholesterol, offering face validity to the results of genome-wide association studies.[41]

Stages

In AMD there is a progressive accumulation of characteristic yellow deposits, called drusen (buildup of extracellular proteins and lipids), in the macula (a part of the retina), between the retinal pigment epithelium and the underlying choroid which is believed to damage the retina over time. Amyloid beta, which builds up in Alzheimer's disease brains, is one of the proteins that accumulate in AMD, which is a reason why AMD is sometimes called "Alzheimer's of the eye" or "Alzheimer's of the retina".[42] AMD can be divided into 3 stages: early, intermediate, and late, based partially on the extent (size and number) of drusen.[1]

AMD-like pathology begins with small yellow deposits (drusen) in the macula, between the retinal pigment epithelium and the underlying choroid. Most people with these early changes (referred to as age-related maculopathy) still have good vision. People with drusen may or may not develop AMD, in fact, the majority of people over age 60 have drusen with no adverse effects. The risk of developing symptoms is higher when the drusen are large and numerous and associated with the disturbance in the pigmented cell layer under the macula. Large and soft drusen are thought to be related to elevated cholesterol deposits.

Early AMD

Early AMD is diagnosed based on the presence of medium-sized drusen, about the width of an average human hair. Early AMD is usually asymptomatic.[1]

Intermediate AMD

Intermediate AMD is diagnosed by large drusen and/or any retinal pigment abnormalities. Intermediate AMD may cause some vision loss, but, like early AMD, it is usually asymptomatic.[1][43]

Late AMD

In late AMD, enough retinal damage occurs that people have symptomatic central vision loss in addition to drusen. The damage can either be the development of atrophy or the onset of neovascular disease. Late AMD is further divided into two subtypes based on the types of damage: Geographic atrophy and Wet AMD (also called Neovascular AMD).[43][1]

Dry AMD

Dry AMD (also called nonexudative AMD) is a broad designation, encompassing all forms of AMD that are not neovascular (wet AMD). This includes early and intermediate forms of AMD, as well as the advanced form of dry AMD known as geographic atrophy. Dry AMD patients tend to have minimal symptoms in the earlier stages; visual function loss occurs more often if the condition advances to geographic atrophy. Dry AMD accounts for 80–90% of cases and tends to progress slowly. In 10–20% of people, dry AMD progresses to the wet type.

Geographic Atrophy

Geographic atrophy (also called atrophic AMD) is an advanced form of AMD in which progressive and irreversible loss of retinal cells leads to a loss of visual function.

Wet AMD

Neovascular or exudative AMD, the "wet" form of advanced AMD, causes vision loss due to abnormal blood vessel growth (choroidal neovascularization) in the choriocapillaris, through Bruch's membrane. It is usually, but not always, preceded by the dry form of AMD. The proliferation of abnormal blood vessels in the retina is stimulated by vascular endothelial growth factor (VEGF). Unfortunately, because these blood vessels are abnormal, these new vessels are fragile, ultimately leading to blood and protein leakage below the macula. Bleeding, leaking, and scarring from these blood vessels eventually cause irreversible damage to the photoreceptors and rapid vision loss if left untreated.

Oxidative stress

Age-related accumulation of low-molecular-weight, phototoxic, pro-oxidant melanin oligomers within lysosomes in the retinal pigment epithelium (RPE) may be partly responsible for decreasing the digestive rate of photoreceptor outer rod segments (POS) by the RPE – autophagy. A decrease in the digestive rate of POS has been shown to be associated with lipofuscin formation – a classic sign associated with AMD.[44][45]

The role of retinal oxidative stress in the cause of AMD by resulting in further inflammation of the macula is suggested by the enhanced rate of disease in smokers and those exposed to UV irradiation.[10][46][47]

Mitochondrial dysfunction may play a role.[48]

Diagnosis

Super resolution microscopic investigation of human eye tissue affected by AMD

Diagnosis of age-related macular degeneration rests on signs in the macula, irrespective of visual acuity. Diagnosis of AMD may include the following procedures and tests:

  • The transition from dry to wet AMD can happen rapidly, and if it is left untreated can lead to legal blindness in as little as six months. To prevent this from occurring and to initiate preventive strategies earlier in the disease process, dark adaptation testing may be performed. A dark adaptometer can detect subclinical AMD at least three years earlier than it is clinically evident.[49]

[50]

Histology

  • Pigmentary changes in the retina – In addition to the pigmented cells in the iris (the colored part of the eye), there are pigmented cells beneath the retina. As these cells break down and release their pigment, dark clumps of released pigment and later, areas that are less pigmented may appear
  • Exudative changes: hemorrhages in the eye, hard exudates, subretinal/sub-RPE/intraretinal fluid
  • Drusen, tiny accumulations of extracellular material that build up on the retina. While there is a tendency for drusen to be blamed for the progressive loss of vision, drusen deposits can be present in the retina without vision loss. Some patients with large deposits of drusen have normal visual acuity. If normal retinal reception and image transmission are sometimes possible in a retina when high concentrations of drusen are present, then, even if drusen can be implicated in the loss of visual function, there must be at least one other factor that accounts for the loss of vision.

Prevention

A 2017 Cochrane review found the use of vitamin and mineral supplements, alone or in combination, by the general population did not affect whether or not AMD started.[4]

Management

Supplements that include lutein and zeaxanthin may slow down the worsening of AMD.[5][53] They have, however, not been shown to prevent the disease.[53] There is not enough evidence to determine if statins have a role in preventing or slowing the progression of AMD.[54] Antiangiogenic steroids such as anecortave acetate and triamcinolone acetonide have shown no evidence in preventing visual loss in people with neovascular AMD.[55]

Dry AMD

No medical or surgical treatment is available for this condition.

Wet AMD

It can be treated with laser coagulation, and more commonly with medication that stops and sometimes reverses the growth of blood vessels.[56][57]

A randomized control trial found that bevacizumab and ranibizumab had similar efficacy, and reported no significant increase in adverse events with bevacizumab.[58] A 2014 Cochrane review found that the systemic safety of bevacizumab and ranibizumab are similar when used to treat neovascular AMD, except for gastrointestinal disorders.[59] Bevacizumab however is not FDA approved for treatment of macular degeneration. A controversy in the UK involved the off-label use of cheaper bevacizumab over the approved, but expensive, ranibizumab.[60] Ranibizumab is a smaller fragment, Fab fragment, of the parent bevacizumab molecule specifically designed for eye injections. Other approved antiangiogenic drugs for the treatment of neo-vascular AMD include pegaptanib[61] and aflibercept.[62]

The American Academy of Ophthalmology practice guidelines do not recommend laser coagulation therapy for macular degeneration, but state that it may be useful in people with new blood vessels in the choroid outside of the fovea who don't respond to drug treatment.[63][64] There is strong evidence that laser coagulation will result in the disappearance of drusen but does not affect choroidal neovascularisation.[65] A 2007 Cochrane review on found that laser photocoagulation of new blood vessels in the choroid outside of the fovea is effective and economical method, but that the benefits are limited for vessels next to or below the fovea.[66]

Photodynamic therapy has also been used to treat wet AMD.[67] The drug verteporfin is administered intravenously; light of a certain wavelength is then applied to the abnormal blood vessels. This activates the verteporfin destroying the vessels.

Cataract surgery could improve visual outcomes for people with AMD, though there have been concerns about surgery increasing the progression of AMD. A randomized controlled trial found that people who underwent immediate cataract surgery (within two weeks) had improved visual acuity and better quality of life outcomes than those who underwent delayed cataract surgery (6 months).[68]

Adaptive devices

Josef Tal, an Israeli composer who was affected by macular degeneration, checks a manuscript using a CCTV desktop unit.

Because peripheral vision is not affected, people with macular degeneration can learn to use their remaining vision to partially compensate.[69] Assistance and resources are available in many countries and every state in the U.S.[70] Classes for "independent living" are given and some technology can be obtained from a state department of rehabilitation.

Adaptive devices can help people read. These include magnifying glasses, special eyeglass lenses, computer screen readers, and TV systems that enlarge reading the material.

Computer screen readers such as JAWS or Thunder work with standard Windows computers. Also, Apple devices provide a wide range of features (voice-over, screen readers, Braille etc.

Video cameras can be fed into standard or special-purpose computer monitors, and the image can be zoomed in and magnified. These systems often include a movable table to move the written material.

Accessible publishing provides larger fonts for printed books, patterns to make tracking easier, audiobooks and DAISY books with both text and audio.

Epidemiology

Disability-adjusted life year for macular degeneration and other (sense organ diseases) per 100,000 inhabitants in 2004[71]
  no data
  less than 100
  100–114
  114–128
  128–142
  142–156
  156–170
  170–184
  184–198
  198–212
  212–226
  226–240
  more than 240

Age-related macular degeneration accounts for more than 54% of all vision loss in the white population in the USA. An estimated 8 million Americans are affected with early age-related macular degeneration, of whom over 1 million will develop advanced age-related macular degeneration within the next 5 years. In the UK, age-related macular degeneration is the cause of blindness in almost 42% of those who go blind aged 65–74 years, almost two-thirds of those aged 75–84 years, and almost three-quarters of those aged 85 years or older.

Macular degeneration is more likely to be found in Caucasians than in people of African descent.[72][73]

Research directions

Studies indicate drusen associated with AMD are similar in molecular composition to Beta-Amyloid (βA) plaques and deposits in other age-related diseases such as Alzheimer's disease and atherosclerosis. This suggests that similar pathways may be involved in the etiologies of AMD and other age-related diseases.[74]

Genetic testing

A practical application of AMD-associated genetic markers is in the prediction of progression of AMD from early stages of the disease to neovascularization.[75][76]

Stem cell transplant

See also: Adeno associated virus and gene therapy of the human retina

Cell based therapies using bone marrow stem cells as well as retinal pigment epithelial transplantation are being studied.[77] A number of trials have occurred in humans with encouraging results.[78]

Other types

There are a few other (rare) kinds of macular degeneration with similar symptoms but unrelated in etiology to Wet or Dry age-related macular degeneration. They are all genetic disorders that may occur in childhood or middle age.

  • Best's disease
  • Sorsby's fundus dystrophy is an autosomal dominant, retinal disease characterized by sudden acuity loss resulting from untreatable submacular neovascularisation
  • Stargardt's disease (juvenile macular degeneration, STGD) is an autosomal recessive retinal disorder characterized by juvenile-onset macular dystrophy, alterations of the peripheral retina, and subretinal deposition of lipofuscin-like material.

Similar symptoms with a very different etiology and different treatment can be caused by epiretinal membrane or macular pucker or any other condition affecting the macula, such as central serous retinopathy.

Notable cases

See also

References

  1. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab "Facts About Age-Related Macular Degeneration". National Eye Institute. June 2015. Archived from the original on 22 December 2015. Retrieved 21 December 2015. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  2. ^ a b GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282. {{cite journal}}: |first1= has generic name (help)CS1 maint: numeric names: authors list (link)
  3. ^ a b c Mehta, S (September 2015). "Age-Related Macular Degeneration". Primary care. 42 (3): 377–91. doi:10.1016/j.pop.2015.05.009. PMID 26319344.
  4. ^ a b Evans, JR; Lawrenson, JG (30 July 2017). "Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration". The Cochrane Database of Systematic Reviews. 7: CD000253. doi:10.1002/14651858.CD000253.pub4. PMID 28756617.
  5. ^ a b Evans, JR; Lawrenson, JG (14 November 2012). "Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration". The Cochrane Database of Systematic Reviews. 11: CD000254. doi:10.1002/14651858.CD000254.pub3. PMID 23152201.
  6. ^ Global Burden of Disease Study 2013, Collaborators (22 August 2015). "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 386 (9995): 743–800. doi:10.1016/s0140-6736(15)60692-4. PMC 4561509. PMID 26063472. {{cite journal}}: |first1= has generic name (help)CS1 maint: numeric names: authors list (link)
  7. ^ Roberts, DL (September 2006). "The First Year – Age Related Macular Degeneration". Marlowe & Company: 100.
  8. ^ Roberts, DL (September 2006). "The First Year – Age Related Macular Degeneration". Marlowe & Company: 20.
  9. ^ Deangelis MM, Silveira AC, Carr EA, Kim IK (2011). "Genetics of age-related macular degeneration: current concepts, future directions". Seminars in ophthalmology. 26 (3): 77–93. doi:10.3109/08820538.2011.577129. PMC 4242505. PMID 21609220.
  10. ^ a b Thornton, J; Edwards, R; Mitchell, P; Harrison, RA; Buchan, I; Kelly, SP (September 2005). "Smoking and age-related macular degeneration: a review of association". Eye (London, England). 19 (9): 935–44. doi:10.1038/sj.eye.6701978. PMID 16151432.
  11. ^ Cougnard-Grégoire, A (March 2013). "Long-term blood pressure and age-related macular degeneration: the ALIENOR study". Invest Ophthalmol Vis Sci. 54 (3): 1905–12. doi:10.1167/iovs.12-10192. PMID 23404120. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
  12. ^ Dasari, Bhanu; Prasanthi, Jaya RP; Marwarha, Gurdeep; Singh, Brij B; Ghribi, Othman (18 August 2011). "Cholesterol-enriched diet causes age-related macular degeneration-like pathology in rabbit retina". BMC Ophthalmology. 11: 22. doi:10.1186/1471-2415-11-22. PMC 3170645. PMID 21851605.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  13. ^ Adams MK, Simpson JA, Aung KZ, et al. (1 June 2011). "Abdominal obesity and age-related macular degeneration". Am J Epidemiol. 173 (11): 1246–55. doi:10.1093/aje/kwr005. PMID 21422060. Retrieved 29 July 2012.
  14. ^ Parekh N, Voland RP, Moeller SM, et al. (November 2009). "Association between dietary fat intake and age-related macular degeneration in the Carotenoids in Age-Related Eye Disease Study (CAREDS): an ancillary study of the Women's Health Initiative". Arch. Ophthalmol. 127 (11): 1483–93. doi:10.1001/archophthalmol.2009.130. PMC 3144752. PMID 19901214.
  15. ^ John Paul SanGiovanni; Emily Y. Chew; Traci E. Clemons; Matthew D. Davis; Frederick L. Ferris III; Gary R. Gensler; Natalie Kurinij; Anne S. Lindblad; Roy C. Milton; Johanna M. Seddon; Robert D. Sperduto (May 5, 2007). "The Relationship of Dietary Lipid Intake and Age-Related Macular Degeneration in a Case-Control Study". Archives of Ophthalmology. Archived from the original on May 23, 2007. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  16. ^ Khan JC, Shahid H, Thurlby DA, Bradley M, Clayton DG, Moore AT, Bird AC, Yates JR, Genetic Factors in AMD Study (January 2006). "Age related macular degeneration and sun exposure, iris colour, and skin sensitivity to sunlight". The British Journal of Ophthalmology. 90 (1): 29–32. doi:10.1136/bjo.2005.073825. PMC 1856929. PMID 16361662.
  17. ^ Glazer-Hockstein, C; Dunaief JL (January 2006). "Could blue light-blocking lenses decrease the risk of age-related macular degeneration?". Retina. 26 (1): 1–4. doi:10.1097/00006982-200601000-00001. PMID 16395131.
  18. ^ Margrain, TH; Boulton M; Marshall J; Sliney DH (September 2004). "Do blue light filters confer protection against age-related macular degeneration?". Progress in Retinal and Eye Research. 23 (5): 523–31. doi:10.1016/j.preteyeres.2004.05.001. PMID 15302349.
  19. ^ Maller, J (September 2006). "Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration". Nat. Genet. 38 (9): 1055–59. doi:10.1038/ng1873. PMID 16936732. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
  20. ^ Edwards, Albert (15 April 2005). "Complement Factor H Polymorphism and Age-Related Macular Degeneration". Science. 308: 421–424. doi:10.1126/science.1110189. PMID 15761121.
  21. ^ Hughes, Anne E; Orr, Nick; Esfandiary, Hossein; Diaz-Torres, Martha; Goodship, Timothy; Chakravarthy, Usha (2006). "A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration". Nature Genetics. 38 (10): 1173–77. doi:10.1038/ng1890. PMID 16998489.
  22. ^ Fritsche, L. G.; Lauer, N.; Hartmann, A.; Stippa, S.; Keilhauer, C. N.; Oppermann, M.; Pandey, M. K.; Kohl, J.; Zipfel, P. F. (2010). "An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD)". Human Molecular Genetics. 19 (23): 4694–4704. doi:10.1093/hmg/ddq399. PMID 20843825. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
  23. ^ Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, Clayton DG, Hayward C, Morgan J, Wright AF, Armbrecht AM, Dhillon B, Deary IJ, Redmond E, Bird AC, Moore AT (2007). "Complement C3 Variant and the Risk of Age-Related Macular Degeneration". N Engl J Med. 357 (6): 553–61. doi:10.1056/NEJMoa072618. PMID 17634448.
  24. ^ Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM (2007). "Variation in Complement Factor 3 is Associated with Risk of Age-Related Macular Degeneration". Nature Genetics. 39 (10): 1200–01. doi:10.1038/ng2131. PMID 17767156.
  25. ^ Yang Z, Camp NJ, Sun H, Tong Z, Gibbs D, Cameron DJ, Chen H, Zhao Y, Pearson E, et al. (Nov 2006). "A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration". Science. 314 (5801): 992–93. doi:10.1126/science.1133811. PMID 17053109.
  26. ^ Dewan A, Liu M, Hartman S, et al. (November 2006). "HTRA1 Promoter Polymorphism in Wet Age-Related Macular Degeneration". Science. 314 (5801): 989–92. doi:10.1126/science.1133807. PMID 17053108.
  27. ^ Hirschler, Ben (2008-10-07). "Gene discovery may help hunt for blindness cure". Reuters. Archived from the original on October 11, 2008. Retrieved 2008-10-07. {{cite news}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  28. ^ Udar N, Atilano SR, Memarzadeh M, Boyer D, Chwa M, Lu S (2009). "Mitochondrial DNA Haplogroups Associated with Age-Related Macular Degeneration". Invest Ophthalmol Vis Sci. 50 (6): 2966–74. doi:10.1167/iovs.08-2646. PMID 19151382.
  29. ^ Canter JA, Olson LM, Spencer K, Schnetz-Boutaud N, Anderson B, Hauser MA (2008). Nicholas Weedon M (ed.). "Mitochondrial DNA polymorphism A4917G is independently associated with age-related macular degeneration". PLoS ONE. 3 (5): e2091. doi:10.1371/journal.pone.0002091. PMC 2330085. PMID 18461138.{{cite journal}}: CS1 maint: unflagged free DOI (link) Open access icon
  30. ^ Mullins RF, Russell SR, Anderson DH, Hageman GS (2000). "Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease". FASEB J. 14 (7): 835–46. PMID 10783137.
  31. ^ Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI (2005). "A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration". Proc Natl Acad Sci USA. 102 (20): 7227–32. doi:10.1073/pnas.0501536102. PMC 1088171. PMID 15870199.
  32. ^ Chen LJ, Liu DT, Tam PO, Chan WM, Liu K, Chong KK (2006). "Association of complement factor H polymorphisms with exudative age-related macular degeneration". Mol. Vis. 12: 1536–42. PMID 17167412.
  33. ^ Despriet DD, Klaver CC, Witteman JC, Bergen AA, Kardys I, de Maat MP (2006). "Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration". JAMA. 296 (3): 301–09. doi:10.1001/jama.296.3.301. PMID 16849663.
  34. ^ Li M, Tmaca-Sonmez P, Othman M, Branham KE, Khanna R, Wade MS (2006). "CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration". Nature Genetics. 38 (9): 1049–54. doi:10.1038/ng1871. PMC 1941700. PMID 16936733.
  35. ^ Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P (2005). "Complement factor H variant increases the risk of age-related macular degeneration". Science. 308 (5720): 419–21. doi:10.1126/science.1110359. PMID 15761120.
  36. ^ Rohrer B, Long Q, Coughlin B, Renner B, Huang Y, Kunchithapautham K (2010). "A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration". Adv Exp Med Biol. Advances in Experimental Medicine and Biology. 703: 137–49. doi:10.1007/978-1-4419-5635-4_10. ISBN 978-1-4419-5634-7. PMID 20711712.
  37. ^ Kunchithapautham K, Rohrer B (May 2011). "Sublytic Membrane-Attack-Complex (MAC) Activation Alters Regulated Rather than Constitutive Vascular Endothelial Growth Factor (VEGF) Secretion in Retinal Pigment Epithelium Monolayers". J Biol Chem. 286 (27): 23717–24. doi:10.1074/jbc.M110.214593. PMC 3129152. PMID 21566137.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  38. ^ Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H (2007). "Complement C3 variant and the risk of age-related macular degeneration". NEJM. 357 (6): 553–61. doi:10.1056/NEJMoa072618. PMID 17634448.
  39. ^ Fritsche LG, Loenhardt T, Janssen A, Fisher SA, Rivera A, Keilhauer CN (2008). "Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA DNA damage and repair in age-related macular degeneration". Nat. Genet. 40 (7): 892–96. doi:10.1038/ng.170.
  40. ^ Chen W, Stambolian D, Edwards AO, Branham KE, Othman M, Jakobsdottir J (2010). "Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration". Proc Natl Acad Sci USA. 107 (16): 7401–06. doi:10.1073/pnas.0912702107. PMC 2867722. PMID 20385819.
  41. ^ Neale BM, Fagerness J, Reynolds R, Sobrin L, Parker M, Raychaudhuri S (2010). "Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC)". Proc Natl Acad Sci USA. 107 (16): 7395–400. doi:10.1073/pnas.0912019107. PMC 2867697. PMID 20385826.
  42. ^ Ratnayaka JA, Serpell LC, Lotery AJ (2015). "Dementia of the eye: the role of amyloid beta in retinal degeneration". Eye (Lond). 29: 1013–26. doi:10.1038/eye.2015.100. PMC 4541342. PMID 26088679.
  43. ^ a b Ferris, Frederick L.; Wilkinson, C.P.; Bird, Alan; Chakravarthy, Usha; Chew, Emily; Csaky, Karl; Sadda, SriniVas R. (2013). "Clinical Classification of Age-related Macular Degeneration". Ophthalmology. 120 (4): 844–851. doi:10.1016/j.ophtha.2012.10.036. ISSN 0161-6420.
  44. ^ "Melanin aggregation and polymerization: possible implications in age related macular degeneration." Ophthalmic Research, 2005; vol. 37: pp. 136–41.
  45. ^ John Lacey, "Harvard Medical signs agreement with Merck to develop potential therapy for macular degeneration Archived 2007-06-07 at the Wayback Machine", 23 May 2006
  46. ^ Tomany SC, Cruickshanks KJ, Klein R, Klein BE, Knudtson MD (2004). "Sunlight and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Study". Arch Ophthalmol. 122 (5): 750–7. doi:10.1001/archopht.122.5.750. PMID 15136324.
  47. ^ Szaflik JP, Janik-Papis K, Synowiec E, Ksiazek D, Zaras M, Wozniak K (2009). "DNA damage and repair in age-related macular degeneration". Mutat Res. 669 (1–2): 167–76. doi:10.1016/j.mrfmmm.2009.06.008.
  48. ^ Barot, M; Gokulgandhi, MR; Mitra, AK (December 2011). "Mitochondrial dysfunction in retinal diseases". Current Eye Research. 36 (12): 1069–77. doi:10.3109/02713683.2011.607536. PMC 4516173. PMID 21978133.
  49. ^ a b Owsley, Cynthia; McGwin, Gerald; Clark, Mark E.; Jackson, Gregory R.; Callahan, Michael A.; Kline, Lanning B.; Witherspoon, C. Douglas; Curcio, Christine A. (2016). "Delayed Rod-Mediated Dark Adaptation Is a Functional Biomarker for Incident Early Age-Related Macular Degeneration". Ophthalmology. 123 (2): 344–351. doi:10.1016/j.ophtha.2015.09.041. ISSN 0161-6420.
  50. ^ Owsley, Cynthia (October 30, 2015). "Delayed Rod-Mediated Dark Adaptation Is a Functional Biomarker for Incident Early Age-Related Macular Degeneration". Ophthalmology. 123: 344–51. doi:10.1016/j.ophtha.2015.09.041.
  51. ^ http://www.revoptom.com/index.asp?page=2_14021.htm. Retrieved August 4, 2009. {{cite web}}: Missing or empty |title= (help)[dead link‍]
  52. ^ "Preferential Hyperacuity Perimetry (PHP) as an Adjunct Diagnostic Tool to Funduscopy in Age–related Macular Degeneration – Ophthalmology Technology Spotlight". Medcompare. Retrieved 2011-01-11.
  53. ^ a b Hobbs, RP; Bernstein, PS (2013). "Nutrient Supplementation for Age-related Macular Degeneration, Cataract, and Dry Eye". Journal of ophthalmic & vision research. 9 (4): 487–93. doi:10.4103/2008-322X.150829. PMC 4329711. PMID 25709776.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  54. ^ Gehlbach P, Li T, Hatef E (2016). "Statins for age-related macular degeneration". Cochrane Database Syst Rev (8): CD006927. doi:10.1002/14651858.CD006927.pub5. PMC 5029465. PMID 27490232.
  55. ^ Geltzer A, Turalba A, Vedula SS (2013). "Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration". Cochrane Database Syst Rev. 1: CD005022. doi:10.1002/14651858.CD005022.pub3. PMC 4269233. PMID 23440797.
  56. ^ de Jong PT (2006). "Age-related macular degeneration". N Engl J Med. 355 (14): 1474–85. doi:10.1056/NEJMra062326. PMID 17021323.
  57. ^ Ch. 25, Disorders of the Eye, Jonathan C. Horton, in Harrison's Principles of Internal Medicine, 16th ed.
  58. ^ Chakravarthy, U; Harding, SP; Rogers, CA; Downes, SM; Lotery, AJ; Culliford, LA; Reeves, BC; on behalf of the IVAN study, investigators (Jul 18, 2013). "Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial". Lancet. 382 (9900): 1258–67. doi:10.1016/S0140-6736(13)61501-9. PMID 23870813.
  59. ^ Moja, L; Lucenteforte, E; Kwag, KH; Bertele, V; Campomori, A; Chakravarthy, U; D'Amico, R; Dickersin, K; Kodjikian, L; Lindsley, K; Loke, Y; Maguire, M; Martin, DF; Mugelli, A; Mühlbauer, B; Püntmann, I; Reeves, B; Rogers, C; Schmucker, C; Subramanian, ML; Virgili, G (Sep 15, 2014). "Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration". The Cochrane Database of Systematic Reviews. 9: CD011230. doi:10.1002/14651858.CD011230.pub2. PMC 4262120. PMID 25220133.
  60. ^ Copley, Caroline; Hirschler, Ben (April 24, 2012). "Novartis challenges UK Avastin use in eye disease". Reuters. Archived from the original on May 22, 2013. {{cite news}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  61. ^ "FDA Approves New Drug Treatment for Age-Related Macular Degeneration". FDA.gov. U.S. Food and Drug Administration. Archived from the original on 2015-11-20. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  62. ^ FDA approves Eylea for macular degeneration Archived 2013-05-28 at the Wayback Machine
  63. ^ "Age-Related Macular Degeneration PPP – Updated 2015". American Academy of Ophthalmology Preferred Practice Pattern. 29 January 2015. Archived from the original on 21 October 2016. Retrieved 22 October 2016. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  64. ^ Lindsley, K; Li, T; Ssemanda, E; Virgili, G; Dickersin, K (April 2016). "Interventions for Age-Related Macular Degeneration: Are Practice Guidelines Based on Systematic Reviews?". Ophthalmology. 123 (4): 884–97. doi:10.1016/j.ophtha.2015.12.004. PMID 26804762.
  65. ^ Virgili G, Michelessi M, Parodi MB, Bacherini D, Evans JR (2015). "Laser treatment of drusen to prevent progression to advanced age-related macular degeneration". Cochrane Database Syst Rev. 10: CD006537. doi:10.1002/14651858.CD006537.pub3. PMC 4733883. PMID 26493180.
  66. ^ Virgili, G; Bini, A (18 July 2007). "Laser photocoagulation for neovascular age-related macular degeneration". The Cochrane Database of Systematic Reviews (3): CD004763. doi:10.1002/14651858.CD004763.pub2. PMID 17636773.
  67. ^ Meads C (2003). "Clinical effectiveness and cost–utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation". Health Technology Assessment. 7 (9). doi:10.3310/hta7090. Archived from the original on 2010-11-07. {{cite journal}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  68. ^ Casparis H, Lindsley K, Kuo IC, Sikder S, Bressler NM (2017). "Surgery for cataracts in people with age-related macular degeneration". Cochrane Database Syst Rev. 2: CD006757. doi:10.1002/14651858.CD006757.pub4. PMC 3480178. PMID 28206671.
  69. ^ "Low Vision Rehabilitation Delivery Model". Mdsupport.org. Archived from the original on 2010-11-07. Retrieved 2011-01-11. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  70. ^ "Agencies, Centers, Organizations, & Societies". Mdsupport.org. 2005-09-01. Archived from the original on 2011-06-11. Retrieved 2011-01-11. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  71. ^ "WHO Disease and injury country estimates". World Health Organization. 2009. Archived from the original on 2009-11-11. Retrieved Nov 11, 2009. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  72. ^ Age-Related Eye Disease Study Research Group (Dec 2000). "Risk Factors Associated with Age-Related Macular Degeneration: A Case-control Study in the Age-Related Eye Disease Study: Age-Related Eye Disease Study Report Number 3". Ophthalmology. 107 (12): 2224–32. doi:10.1016/S0161-6420(00)00409-7. PMC 1470467. PMID 11097601.
  73. ^ Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL (April 2005). "Risk Factors for the Incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS Report No. 19". Ophthalmology. 112 (4): 533–39. doi:10.1016/j.ophtha.2004.10.047. PMC 1513667. PMID 15808240.
  74. ^ Mullins, RF (May 2000). "Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease". FASEB J. 14 (7): 835–46. PMID 10783137. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
  75. ^ Chen W, Stambolian D, Edwards AO, Branham KE, Othman M, Jakobsdottir J (2010). "Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration". Proc Natl Acad Sci USA. 107 (16): 7401–06. doi:10.1073/pnas.0912702107. PMC 2867722. PMID 20385819.
  76. ^ Neale BM, Fagerness J, Reynolds R, Sobrin L, Parker M, Raychaudhuri S (2010). "Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC)". Proc Natl Acad Sci USA. 107 (16): 7395–7400. doi:10.1073/pnas.0912019107. PMC 2867697. PMID 20385826.
  77. ^ John S, et al. (2013). "Choice of cell source in cell based therapies for retinal damage due to age related macular degeneration (AMD): A review". Journal of Ophthalmology. 2013: 1–9. doi:10.1155/2013/465169.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  78. ^ "Development of human embryonic stem cell therapies for age-related macular degeneration". Trends in Neurosciences. 36: 391, 393. doi:10.1016/j.tins.2013.03.006.
  79. ^ "Judi Dench 'can't read any more due to failing eyesight Archived 2016-10-19 at the Wayback Machine", The Guardian, 23 February 2014
  80. ^ "Joan bows out to a standing ovation Archived 2016-04-20 at the Wayback Machine", The Guardian, 13 May 2014
  81. ^ "Patrons of the Macular Society Archived 2013-02-08 at the Wayback Machine", Macular Society. (notable for doing the voice of Wallace from Wallace and Gromit until 2012)
  82. ^ "Roseanne Barr's blindness and how to prevent her diseases Archived 2015-05-11 at the Wayback Machine", CNN
Listen to this article
(2 parts, 12 minutes)
  2. Part 2
Spoken Wikipedia icon
These audio files were created from a revision of this article dated
Error: no date provided
, and do not reflect subsequent edits.
(Audio help · More spoken articles)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Macular_degeneration&oldid=863998698"